N/A Completed N=17 Quadruple-blind Treatment

Treating the Endothelium to Restore Insulin Sensitivity

Obesity · Insulin Resistance · impaired glucose tolerance · Pre-diabetes

Source: ClinicalTrials.gov NCT00402194 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2013

Primary outcomePrimary: Leg Blood Flow Response to Insulin — 0.24; 0.26; 0.353; 0.046 Liters/minute

Summary

A study of 12 weeks' treatment with losartan or placebo, to test the hypothesis that RAS inhibition will improve insulin' vascular actions and therefore improve insulin sensitivity in skeletal muscle.

Outcome Measures

Outcome	Result	p-value
PRIMARY Leg Blood Flow Response to Insulin	0.24; 0.26; 0.353; 0.046	—
PRIMARY Insulin-stimulated Leg Glucose Uptake	0.42; 0.30	—

Eligibility Criteria

Inclusion Criteria

Healthy
Age 20-55
Male and female
Obese, defined as Males: BMI >28 or > 30% fat by DEXA scan or Bod Pod; Females: BMI >30 or > 33% fat by DEXA scan or Bod Pod
Weight stable over at least 4 months

Exclusion Criteria

Diabetes mellitus (ADA criteria)
Age 55 yrs
Blood pressure >160/90 or 240 or LDL cholesterol >160 mg/dL
Baseline elevations in AST or ALT > 3X ULN
Baseline elevation in creatinine >1.6 ng/mL
Unexplained baseline elevation in creatine kinase > 3X ULN
Concurrent significant chronic medical illness including, but not limited to, human immunodeficiency virus infection, Syphilis, hepatitis B infection, or hepatitis C infection
Pregnancy
Known hypersensitivity or intolerance to the study agents

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00402194). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.